ELTX

+ Watchlist + Portfolio

Elicio Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.13
52-Week Range: $2.66 – $16.00
Market Cap: $80.82M
P/E (TTM): —
EPS (TTM): -2.12
Dividend Yield: —

Advanced Metrics

Price/Book: 8.49
PEG Ratio: —
Return on Equity: -774.56%
Return on Assets: -77.88%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 2.77
Debt/Equity: 1.78
Total Debt: $14.15M
Free Cash Flow: $-22.32M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $71.62M

ELTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$18.10M	$23.85M	$33.66M	$24.90M
Selling, General & Admin	$5.63M	$11.90M	$11.33M	$12.81M
Operating Expenses	$23.73M	$35.74M	$44.99M	$37.30M
Operating Income	-$23.73M	-$35.74M	-$44.99M	-$37.30M
EBITDA	-$23.55M	-$32.97M	-$50.27M	-$37.31M
Pretax Income	-$28.21M	-$35.20M	-$51.90M	-$39.57M
Income Tax	—	$0.00	$0.00	$0.00
Net Income	-$28.21M	-$35.20M	-$51.90M	-$39.57M
Diluted EPS	-2.70	-6.96	-4.25	-2.58
Diluted Shares	10.46M	5.06M	12.20M	15.31M

ELTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$6.16M	$12.89M	$17.62M	$18.56M
Current Assets	$10.72M	$16.35M	$20.69M	$19.31M
Total Assets	$22.66M	$27.15M	$28.18M	$25.86M
Current Liabilities	$6.87M	$9.76M	$11.52M	$8.11M
Long-Term Debt	—	—	$20.03M	$9.41M
Total Debt	$7.48M	$6.92M	$26.04M	$14.51M
Total Liabilities	$124.81M	$15.77M	$39.49M	$24.23M
Retained Earnings	-$107.01M	-$142.20M	-$194.10M	-$233.67M
Shareholders' Equity	-$102.14M	$11.37M	-$11.31M	$1.64M
Working Capital	$3.85M	$6.59M	$9.17M	$11.20M
Net Debt	—	—	$2.42M	—

ELTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$22.18M	-$32.69M	-$37.07M	-$36.95M
Capital Expenditure	-$654.00K	-$66.00K	-$87.00K	-$16.00K
Free Cash Flow	-$22.83M	-$32.76M	-$37.16M	-$36.97M
Depreciation & Amortisation	$1.06M	$1.17M	$1.18M	$1.13M
Stock-Based Compensation	$579.00K	$1.18M	$1.45M	$2.70M
Investing Cash Flow	-$654.00K	-$32.00K	-$84.00K	-$16.00K
Financing Cash Flow	$21.20M	$38.61M	$42.32M	$36.70M
Share Repurchases	$0.00	-$150.00K	—	—
Net Change in Cash	-$1.63M	$5.89M	$5.17M	-$273.00K

ELTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$7.78M	$7.01M	$5.04M	$5.08M	$6.76M
Selling, General & Admin	$2.96M	$3.08M	$3.01M	$3.76M	$3.85M
Operating Expenses	$10.74M	$9.68M	$8.04M	$8.84M	$10.60M
Operating Income	-$10.74M	-$9.68M	-$8.04M	-$8.84M	-$10.60M
EBITDA	-$10.76M	-$10.09M	-$9.37M	-$7.09M	-$11.13M
Pretax Income	-$11.21M	-$10.56M	-$10.08M	-$7.72M	-$11.82M
Net Income	-$11.21M	-$10.56M	-$10.08M	-$7.72M	-$11.82M
Diluted EPS	-0.87	-0.66	-0.60	—	-0.65
Diluted Shares	12.95M	16.06M	16.69M	—	18.21M

ELTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$18.35M	$22.09M	$20.61M	$18.56M	$14.95M
Current Assets	$20.93M	$22.60M	$21.46M	$19.31M	$16.20M
Total Assets	$28.14M	$29.53M	$28.28M	$25.86M	$22.69M
Current Liabilities	$11.41M	$9.92M	$6.51M	$8.11M	$7.23M
Long-Term Debt	—	$9.34M	$9.72M	$9.41M	$9.47M
Total Debt	$5.79M	$14.90M	$15.06M	$14.51M	$14.34M
Total Liabilities	$19.24M	$27.69M	$24.47M	$24.23M	$24.13M
Retained Earnings	-$205.31M	-$215.87M	-$225.95M	-$233.67M	-$245.50M
Shareholders' Equity	$8.90M	$1.83M	$3.82M	$1.64M	-$1.44M
Working Capital	$9.52M	$12.68M	$14.95M	$11.20M	$8.97M

ELTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$10.12M	-$8.95M	-$11.09M	-$6.80M	-$11.64M
Free Cash Flow	-$10.12M	-$8.95M	-$11.09M	-$6.81M	-$11.64M
Depreciation & Amortisation	$278.00K	$281.00K	$283.00K	$286.00K	$289.00K
Stock-Based Compensation	$517.00K	$710.00K	$698.00K	$772.00K	$868.00K
Investing Cash Flow	$0.00	$0.00	$0.00	-$16.00K	—
Financing Cash Flow	$10.33M	$11.93M	$9.57M	$4.86M	$8.03M
Net Change in Cash	$209.00K	$2.98M	-$1.51M	-$1.95M	-$3.62M

Market Snapshot

About

Elicio Therapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer treatment. The company's proprietary Amphiphile (AMP) platform technology is designed to direct immune responses to lymph nodes, where T cells are activated. Elicio's lead programs focus on cancer vaccines and immunomodulatory therapies that aim to generate robust and durable anti-tumor immune responses. The company is conducting clinical trials in multiple cancer types, including pancreatic cancer and other solid tumors with significant unmet medical needs.